First Patient Dosed in Ph I/II BEXMAB Combo Study
Faron Pharmaceuticals Ltd (“Faron or Company”) Faron Pharmaceuticals Doses First Patient in Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies Press Release, June 08, 2022 at 02:00 AM (EST) / 07:00 AM (BST) / 09:00 AM (EEST) TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that the first patient has been dosed in the Phase